BSE: 544409
ASTONEA LABS LIMITED
Manufactures and sells pharmaceutical products from a facility at Village Haripur, Panchkula, Haryana, generating Rs 147.58 crore in FY26 revenue, up 51% from Rs 97.52 crore the year before. The revenue base is built on third-party manufacturing orders combined with own-brand distribution, with the company investing in distribution channels and brand building during the year. Profitability softened: standalone EBITDA fell to Rs 13.80 crore (margin 9.35%) and standalone PAT slipped to Rs 4.52 crore, while consolidated PAT rose to Rs 5.35 crore. A fire on 27 April 2026 at the Panchkula factory caused Rs 9.39 crore of damage to building, plant, machinery and stocks, with the insurance claim still pending. Capital from a Rs 37.67 crore IPO in June 2025 was partly redirected into a 25.74% stake in Damaira Pharmaceuticals (Rs 6.25 crore) and into a US subsidiary, Astonea LLC in Wyoming, while the company also terminated its agreements with Astonea One Private Limited. AR · MarketPing reader · 2026-08-02
Revenue streams, as the annual report describes them. Pharmaceutical manufacturing and sales. Small-cap pharmaceutical manufacturer on BSE SME, growing top line but with margin pressure and a recent uninsured factory fire loss.
Exhibit 1: Financial summary, FY26–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY26 |
|---|---|
| Revenue | 148 |
| EBITDA (ex other income) | — |
| margin % | — |
| Owners' profit | — |
| EPS, as reported (₹) | 4.49 |
| ROE % · ROCE % | — · 11.3 |
| Debt / equity (x) | — |
| Cash from operations | (14) |
| Capex | (14) |
Exhibit 2: Quarterly performance, last 1 quarters
| ₹ crore | Q4 FY26 |
|---|---|
| Revenue | 81 |
| Profit before tax | 4 |
| Net profit | — |
| EPS (₹) | 3.08 |
Exhibit 3: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,20,165 | 34.8 | 5.01 | 22.5 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,51,896 | 86.3 | 15.03 | 65.0 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,56,538 | 73.9 | 8.90 | 38.9 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,17,055 | 26.1 | 3.96 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| LAURUS LABS LIMITED | 1,15,722 | 105.7 | 21.31 | 64.4 | 16.4 | 17.2 | 7.2 | 32.0 |
| DR. REDDY S LABORATORIES | 1,09,385 | 33.9 | 2.86 | 14.6 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,09,060 | 32.3 | 3.16 | 16.7 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,03,353 | 50.6 | 6.24 | 28.4 | 11.7 | 10.8 | — | 27.3 |
Exhibit 4: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 104.9 | 30.1 | 143 of 158 | 10% |
| ROCE | 7.2 | 10.8 | 116 of 183 | 37% |
| Market cap | 340 | 810 | 103 of 181 | 43% |
Exhibit 5: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 9 Oct 2026 · Change in Corporate Identification Number (CIN) after altering Object Clause | compliance | low | — | — |
| 8 Oct 2026 · Astonea Labs incorporates new subsidiary Longevity Science Pvt Ltd | strategic transactions | medium | — | — |
| 8 Oct 2026 · Routine SEBI Reg 74(5) certificate filing for Q2 FY27 | compliance | minimal | — | — |
| 25 Sept 2026 · Trading window closed from Oct 1 ahead of H2 results | compliance | minimal | — | — |
| 22 Sept 2026 · Resubmission of H2 and FY25 audited financial results | results | high | — | — |
| 19 Sept 2026 · Astonea Labs resubmits FY25 results in PDF; PAT up 31% on 21% revenue growth | results | medium | — | — |
| 18 Sept 2026 · Promoter Ashish Gulati buys 14,000 shares of Astonea Labs in open market | ownership changes | medium | — | — |
| 17 Sept 2026 · Promoter Ashish Gulati buys 14,000 shares of Astonea Labs | ownership changes | medium | — | — |
| 17 Sept 2026 · Promoter Ashish Gulati acquires 14,000 shares of Astonea Labs via open market | ownership changes | high | — | — |
| 9 Sept 2026 · Appointment of Internal Auditor for FY 2026-27 | management changes | medium | — | — |
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.